Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
20 Giugno 2024 - 1:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that members of the Company’s management
team will participate in a fireside chat at the Piper Sandler 2nd
Annual Virtual Obesity Investor Day, being held on June 26, 2024,
to discuss key takeaways from the American Diabetes Association’s
(ADA) Scientific Sessions. Details on the fireside chat are as
follows:
|
Title: |
Piper Sandler Virtual Obesity Investor Day |
|
|
|
|
Presenters: |
Vipin Garg, Ph.D., Chief
Executive OfficerScott Roberts, Ph.D., Chief Scientific
Officer |
|
|
|
|
Date/Time: |
Wednesday, June 26, 2024 at 9:30
a.m. EDT |
|
|
The session will be webcast and can be accessed by visiting the
Events section of the Altimmune website.
About AltimmuneAltimmune is a clinical-stage
biopharmaceutical company focused on developing innovative
next-generation peptide-based therapeutics. The Company is
developing pemvidutide, a GLP-1/glucagon dual receptor agonist for
the treatment of obesity and MASH. For more information, please
visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Company Contact:Richard EisenstadtChief
Financial OfficerPhone: 240-654-1450ir@altimmune.com
Investor Contacts:Lee RothBurns McClellanPhone:
646-382-3403lroth@burnsmc.com Julia WeilmanBurns McClellanPhone:
646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke
CommsPhone: 619-826-4657Danielle.cantey@inizioevoke.com
Grafico Azioni Altimmune (NASDAQ:ALT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Altimmune (NASDAQ:ALT)
Storico
Da Giu 2023 a Giu 2024
